| 78 | 0 | 103 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探究不同疾病呈现的抗苗勒管激素(AMH)水平异常升高的程度和特点，以及AMH作为标志物的临床意义。方法 回顾性分析2024年北京协和医院检验科检出的AMH>20 ng/ml的女性病例的临床诊断资料，比较不同疾病AMH水平的差异。结果 本研究纳入了120例AMH>20 ng/ml的病例，相关诊断归为多囊卵巢综合征(PCOS)、卵巢颗粒细胞瘤和性发育异常(DSD)三大类，三类病例AMH的平均水平分别为(23.96±4.26) ng/ml、(67.60±61.87) ng/ml和(127.08±70.63) ng/ml,范围值分别为20.05～41.00 ng/ml、20.50～254.00 ng/ml、62.00～230.00 ng/ml,不同类型疾病间AMH水平的差异有统计学意义(P<0.05)。结论 AMH作为卵巢颗粒细胞瘤的肿瘤标志物，在颗粒细胞瘤患者中其水平显著高于PCOS患者，而部分DSD患者的AMH水平异常升高是雄激素合成或功能障碍的标志物，并非肿瘤标志物。
Abstract：Objectives:To explore the degree and characteristics of abnormal elevation of anti-Müllerian hormone(AMH) in different diseases, and the clinical significance of AMH as a marker.Methods:The clinical diagnosis data of female cases with AMH>20 ng/ml tested by the Clinical Laboratory of Peking Union Medical College Hospital in 2024 was retrospectively analyzed, and the differences of AMH levels in different diseases were compared.Results:A total of 120 cases with AMH>20 ng/ml were included and the diagnosis of these cases was classified into three major categories: polycystic ovary syndrome(PCOS),ovarian granulosa cell tumor, and disorders of sexual development(DSD). The average levels of AMH of patients in three categories were(23.96±4.26) ng/ml,(67.60±61.87) ng/ml and(127.08±70.63) ng/ml, the range values were 20.05-41.00 ng/ml, 20.50-254.00 ng/ml and 62.00-230.00 ng/ml, respectively. There was a statistically significant difference in AMH levels among different types of diseases(P<0.05).Conclusions:AMH,as a tumor marker of granulosa cell tumor, has significantly higher levels in granulosa cell tumor patients than in PCOS patients, while the abnormal elevation of AMH in some DSD patients is a marker of androgen synthesis or dysfunction, not a tumor marker.
[1] 欧阳杰，凡永，刘萍.血清HLA-G、PLGF、IL-35对夫精宫腔内人工授精妊娠结局的预测价值[J].生殖医学杂志，2025,34:164-170.
[2] Kitajima M,Kajimura I,Kitajima Y,et al.AMH producing purely cystic virilizing adult granulosa cell tumor in 17 years old girl:a case report and review of literatures[J].J Ovarian Res,2023,16:52.
[3] Moolhuijsen LME,Louwers YV,Laven JSE,et al.Comparison of 3 different AMH assays with AMH levels and follicle count in women with polycystic ovary syndrome[J].J Clin Endocrinol Metab,2022,107:e3714-3722.
[4] 张爱萍，张学红.抗米勒管激素在女性生殖领域的研究进展[J].中国性科学，2025,34:48-53.
[5] Behringer RR,Finegold MJ,Cate RL.Müllerian-inhibiting substance function during mammalian sexual development[J].Cell,1994,79:415-425.
[6] Teede HJ,Tay CT,Laven JJE,et al.Recommendations from the 2023 international evidence-based guide - line for the assessment and management of polyeystic ovary syndrome[J].Eur J Endocrinol,2023,189:G43-64.
[7] Spector I,Derech-Haim S,Boustanai I,et al.Anti-Müllerian hormone signaling in the ovary involves stromal fibroblasts:a study in humans and mice provides novel insights into the role of ovarian stroma[J].Hum Reprod,2024,39:2551-2564.
[8] Wang NF,Mamsen LS,Cadenas J,et al.Impact of female age on concentrations of reproductive hormones and oocyte-specific growth factors in follicular fluid from human small antral follicles[J].Hum Reprod,2025,40:707-716.
[9] Birbas E,Vatopoulou A,Kanavos T,et al.Clinical utility of anti-Müllerian hormone in female children and adolescents[J].Hormones (Athens),2025,24:179-188.
[10] Yoshita S,Osuka S,Shimizu T,et al.Unkeito promotes follicle development by restoring reduced follicle-stimulating hormone responsiveness in rats with polycystic ovary syndrome[J].Front Endocrinol (Lausanne),2023,14:1228088.
[11] 郭锐，张亚杰，傅杨，等.血清抗苗勒管激素水平与正常育龄女性生育力的相关性[J].生殖医学杂志，2025,34:150-156.
[12] Vale-Fernandes E,Pignatelli D,Monteiro MP.Should anti-Müllerian hormone be a diagnosis criterion for polycystic ovary syndrome?An in-depth review of pros and cons[J].Eur J Endocrinol,2025,192:R29-43.
[13] 高富敏，朱海静，陈南侨，等.血清抗苗勒管激素水平对不同年龄患者IVF/ICSI临床结局的影响[J].生殖医学杂志，2024,33:866-872.
[14] 王进，张池，兰天，等.抗苗勒管激素在生殖内分泌领域的研究进展[J].现代妇产科进展，2024,33:317-320.
[15] 冯力元，邓姗.术前抗苗勒管激素水平不能准确预测卵巢子宫内膜异位症囊肿不孕患者术后的生育结局[J].生殖医学杂志，2023,32:991-996.
[16] Rudnicka E,Kunicki M,Calik-Ksepka A,et al.Anti-Müllerian hormone in pathogenesis,diagnostic and treatment of PCOS[J].Int J Mol Sci,2021,22:12507.
[17] Li XL,Ji YF,Feng Y,et al.Metabolic disparities between obese and non-obese patients with polycystic ovary syndrome:implications for endometrial receptivity indicators[J].Gynecol Endocrinol,2024,40:2312895.
[18] Lv PP,Jin M,Rao JP,et al.Role of anti-Müllerian hormone and testosterone in follicular growth:a cross-sectional study[J].BMC Endocr Disord,2020,20:101.
[19] di Clemente N,Racine C,Pierre A,et al.Anti-Müllerian hormone in female reproduction[J].Endocr Rev,2021,42:753-782.
[20] Moolhuijsen LME,Louwers YV,McLuskey A,et al.Association between an AMH promoter polymorphism and serum AMH levels in PCOS patients[J].Hum Reprod,2022,37:1544-1556.
[21] Arabzadeh S,Hossein G,Rashidi BH,et al.Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome[J].Ann Saudi Med,2010,30:442-447.
[22] 田秦杰主编.实用女性生殖内分泌学[M].第3版.北京：人民卫生出版社，2024:567.
[23] Shrikhande L,Shrikhande B,Shrikhande A.AMH and its clinical implications[J].J Obstet Gynaecol India,2020,70:337-341.
[24] Chi H,Huang N,Liang H,et al.Abnormal elevation of anti-Mullerian hormone and androgen levels presenting as granulosa cell tumor[J].Front Oncol,2021,11:641166.
[25] Gustafson ML,Lee MM,Scully RE,et al.Müllerian inhibiting substance as a marker for ovarian sex-cord tumor[J].N Engl J Med,1992,326:466-471.
[26] Rey RA,Lhomme C,Marcillac I,et al.Antimüllerian hormone as a serum marker of granulosa cell tumors of the ovary:comparative study with serum alpha-inhibin and estradiol[J].Am J Obstet Gynecol,1996,174:958-965.
[27] Victoria M,Labrosse J,Krief F,et al.Anti Müllerian hormone:More than a biomarker of female reproductive function[J].J Gynecol Obstet Hum Reprod,2019,48:19-24.
[28] Lee MM,Misra M,Donahoe PK,et al.MIS/AMH in the assessment of cryptorchidism and intersex conditions[J].Mol Cell Endocrinol,2003,211:91-98.
[29] Josso N.Paediatric applications of anti-Müllerian hormone research[J].Horm Res,1995,43:243-248.
[30] Russell N,Gilmore A,Roudebush WE.Clinical utilities of anti-Müllerian hormone[J].J Clin Med,2022,11:7209.
[31] Josso N,Lamarre I,Picard JY,et al.Anti-Müllerian hormone in early human development[J].Early Hum Dev,1993,33:91-99.
[32] Chemes HE,Rey RA,Nistal M,et al.Physiological androgen insensitivity of the fetal,neonatal,and early infantile testis is explained by the ontogeny of the androgen receptor expression in Sertoli cells[J].J Clin Endocrinol Metab,2008,93:4408-4412.
[33] Boukari K,Meduri G,Brailly-Tabard S,et al.Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development[J].J Clin Endocrinol Metab,2009,94:1818-1825.
[34] Grinspon RP,Andreone L,Bedecarrás P,et al.Male central precocious puberty:serum profile of anti-Müllerian hormone and inhibin B before,during,and after treatment with GnRH analogue[J].Int J Endocrinol,2013,2013:823064.
[35] Grinspon RP,Bedecarrás P,Ballerini MG,et al.Early onset of primary hypogonadism revealed by serum anti-Müllerian hormone determination during infancy and childhood in trisomy 21[J].Int J Androl,2011,34:e487-498.
[36] 中华医学会儿科学分会内分泌遗传代谢学组，中华儿科杂志编辑委员会，国家儿童健康与疾病临床医学研究中心.儿童雄激素不敏感综合征诊断和治疗专家共识(2024)[J].中华儿科杂志，2024,62:501-508.
[37] Stuchi-Perez EG,Hackel C,Oliveira LE,et al.Diagnosis of 5 alpha-reductase type 2 deficiency:contribution of anti-Müllerian hormone evaluation[J].J Pediatr Endocrinol Metab,2005,18:1383-1389.
基本信息:
中图分类号:R737.31
引用信息:
[1]张嘉慧,程歆琦,邓姗.120例抗苗勒管激素水平>20 ng/ml女性病例的回顾性分析[J].生殖医学杂志,2025,34(11):1513-1518.
基金信息:
国家临床重点专科建设项目(U114000)